EHL BIO Selected as an Outstanding Corporate Research Institute for 2026, Officially Recognizing Its Research Capabilities and Technological Innovation Achievements

The value of a research institute cannot be assessed solely by the size of its research facilities. It is equally important to examine who is conducting the research and what questions they are addressing, whether research outcomes are being accumulated and developed into technologies, and whether systems are in place to manage safety and quality. This foundation of trust is especially critical in industries such as cell science and regenerative medicine, where research, manufacturing, clinical development, and collaboration with medical institutions involve long and complex processes.

EHL BIO has been selected as a 2026 Outstanding Corporate Research Institute by the Ministry of Science and ICT. This program separately evaluates and designates corporate research institutes that have already received official recognition and demonstrate excellence in R&D capabilities and technological innovation achievements. Its significance lies in going beyond confirmation that an institute meets basic operational requirements, instead comprehensively reviewing ongoing R&D activities and plans to secure future technologies.

The Difference Between Corporate Research Institute Recognition and Outstanding Corporate Research Institute Designation

Corporate Research Institute Recognition is a program that officially recognizes corporate research institutes equipped with the personnel, facilities, and other resources required to conduct R&D. It can be understood as a process that verifies whether the fundamental infrastructure needed to operate a research-focused organization has been established.

Outstanding Corporate Research Institute Designation involves a more advanced and in-depth evaluation. It comprehensively assesses already recognized corporate research institutes based on their R&D capabilities, the expertise of research personnel, research facilities and equipment, scale of R&D investment, technological innovation achievements, ability to secure future technologies, global competitiveness, and plans for sustained R&D investment.

The evaluation considers more than the institute’s internal research environment. It also examines whether accumulated technologies are translating into tangible R&D outcomes, whether future research plans have a sustainable structure, and whether the organization has the potential for external collaboration and global expansion. Because bio companies typically build research assets over the long term, such evaluations can serve as a reference for assessing the direction and execution capabilities of a research organization.

Why Research Credibility Matters in the Bio Sector

Bio R&D cannot be completed through the results of a single experiment. Research involving cells requires the integrated management of source materials, processes, analytical methods, quality control, manufacturing environments, and clinical development strategies. For the potential identified in early-stage research to progress toward possible application in real-world medical settings, verification, documentation, and management systems are needed at every stage.

From a consumer perspective, R&D capabilities are also an important consideration. While terms such as cell-based technology and regenerative medicine may create expectations, it is essential to distinguish between the research stage, clinical trial stage, and the scope of authorized medical services. Research institute designation does not indicate therapeutic effects for a specific disease or the efficacy of a particular product. Rather, it is more appropriate to understand the designation as an evaluation of the R&D institution's capabilities in bio R&D and technological innovation achievements.

For a company, it may serve as a foundation for external collaboration. It can provide objective evidence of research credibility in areas such as investment attraction, technology evaluation, technology assessments for initial public offerings, discussions with overseas partners, and joint research with hospitals and universities. It also helps communicate R&D expertise to external stakeholders.

Research Foundation and Manufacturing Infrastructure Built Since 2012

EHL BIO received Corporate Research Institute certification from the Korea Industrial Technology Association when the company was established in 2012. Since then, it has expanded its capabilities in R&D, clinical development, GMP manufacturing, cell banking, quality testing, and collaboration with domestic and international medical institutions and cell-processing facilities, with a focus on stem cell-based regenerative medicine.

The company's principal R&D areas include research related to intestinal diseases, atopic conditions, anti-aging, and exosomes. Its business structure also includes clinical trials and advanced regenerative medicine clinical research using autologous adipose-derived stem cells and autologous urine-derived stem cells are also included within its business structure. Because each research program differs in its stage of development and scope of application, the progress of individual programs should be confirmed through separate official information.

Manufacturing capabilities are also a key pillar of R&D. EHL BIO completed the K1 GMP Center in 2015 and the K2 GMP Center in 2019. According to internal data, the K1 and K2 GMP Centers have a combined production capacity of 6,600 batches. In 2021, the company obtained licenses from the Ministry of Food and Drug Safety for the Human Cells, etc. Management Business and for a cell-processing facility, with both licenses recorded as the first of their kind in Korea. It also holds ISO 9001:2015 Quality Management System certification.

Quality is an especially important consideration in cell-based research and manufacturing. EHL BIO conducts quality-control testing that includes appearance testing, identification testing, sterility testing, and mycoplasma testing. However, quality standards, testing items, and scopes of application may vary depending on the individual cell or product and its stage of development and applicable regulations. Specific details should therefore be confirmed through official quality documentation.

2026: An Ongoing Record of Clinical Development and Global Collaboration

In 2026, EHL BIO's R&D activities continue across multiple areas. On July 13, an investigator meeting was held for a Phase 3 clinical trial involving the intravenous administration of autologous adipose-derived stem cells for atopic dermatitis. Participating institutions included Korea University Ansan Hospital, Seoul National University Hospital, Soonchunhyang University Cheonan Hospital, Yonsei University Wonju Severance Christian Hospital, Pusan National University Yangsan Hospital, Chosun University Hospital, and Chung-Ang University Hospital.

Phase 3 is a stage of clinical trials conducted as part of the drug development process. The holding of an investigator meeting or the participation of multiple institutions does not itself indicate clinical efficacy or safety outcomes. Clinical trial results and authorization status are determined through established procedures and evaluations. When reviewing clinical trial information, readers should distinguish among the target disease, cell type, route of administration, stage of research, and scope of publicly disclosed results.

Collaboration with the Department of Science, Technology and Training of Vietnam’s Ministry of Health is also being pursued. The collaboration encompasses R&D and technology transfer related to production technologies for cells and cell-derived products. A presentation was also delivered in the Sanur Medical Special Economic Zone in Bali, Indonesia, addressing cooperation with local partners and the establishment of a foundation for the clinical application of cell technologies. Such international collaboration may be viewed as a process through which technologies can be discussed and implemented in alignment with the regulatory systems and healthcare environments of each country.

Evaluating Research Capabilities Is a Commitment to the Future

Selection as an Outstanding Corporate Research Institute is more than a single certification or symbol. It serves as a record demonstrating that R&D personnel and facilities, investment, achievements, and long-term plans have been evaluated together. In the bio industry, such records can help communicate both the foundation and future direction of a company’s research activities to external stakeholders.

For readers with a strong interest in health and biotechnology, it is important to look beyond compelling language and first examine the stages and evidence behind research. Reviewing an institute's designation history, quality management systems, clinical development status, and the scope of officially disclosed information can help readers distinguish reliable information. EHL BIO's selection is noteworthy in that it reflects a national-level evaluation of the research foundation and execution capabilities of an organization that has continued its research in cell-based regenerative medicine.

About EHL BIO

EHL BIO is a biotechnology company dedicated to advancing healthy human lives through stem cell-based regenerative medicine. By scientifically exploring the body's innate capacity for self-recovery, it develops new approaches to aging and disease. By combining premium healthcare with advanced biotechnology, EHL BIO aims to provide solutions for healthier, more vital lives.